Nilotinib Amorphous Solid Dispersions for Food-Independent Dosing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current nilotinib formulations, such as Tasigna®, face challenges including food interactions that affect bioavailability, interindividual variability, and the generation of genotoxic impurities like nilotinib impurity A, posing safety concerns and adherence issues due to strict dosing requirements.
Innovation Solution
Development of amorphous solid dispersions (ASDs) of nilotinib with polymeric stabilizing and matrix-forming components, optionally combined with solid organic acids like ascorbic acid, to enhance stability and reduce food effects, thereby maintaining consistent pharmacokinetics and minimizing impurity formation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If crystalline nilotinib monohydrochloride monohydrate is used in immediate-release capsule formulation, then the drug can be administered orally with simple dosing, but food interactions significantly increase AUC and Cmax leading to QT prolongation and safety concerns
Solution Approach 1:
The patent changes the physical state of nilotinib from crystalline to amorphous form, and modifies the formulation from immediate-release to controlled-release matrix formulation. These parameter changes in drug state and release kinetics eliminate food interactions while maintaining dosing simplicity, as the controlled-release mechanism prevents the spike in plasma concentration that causes QT prolongation when taken with food
Solution Approach 2:
The patent uses a composite matrix formulation containing nilotinib amorphous solid dispersion combined with pH-modifying agents and controlled-release excipients. This composite material system controls drug release independently of food presence, resolving the contradiction between easy dosing and food interaction effects by creating a formulation that maintains stable release characteristics regardless of gastric conditions
2Ease of manufacture
If crystalline nilotinib formulation is used, then manufacturing is straightforward, but the formulation generates genotoxic impurities like nilotinib impurity A posing safety concerns
Solution Approach 1:
The patent changes the crystalline form of nilotinib to an amorphous solid dispersion state. This parameter change in physical form alters the chemical stability and degradation profile of the drug, preventing the formation of genotoxic impurities like nilotinib impurity A that occur with crystalline formulations, while maintaining ease of manufacture through established amorphous dispersion technologies
Solution Approach 2:
The patent converts the potential harm of amorphous form instability into a benefit by using the amorphous state's enhanced solubility and altered degradation pathway to eliminate genotoxic impurity formation. The amorphous solid dispersion, when properly stabilized with polymers, prevents the specific degradation reactions that produce genotoxic byproducts in crystalline forms
3Speed
If immediate-release formulation is used, then rapid drug availability is achieved, but interindividual variability in pharmacokinetics is high reducing treatment consistency
Solution Approach 1:
The patent transitions from immediate-release to controlled-release dynamics, where the drug release rate is modulated by the matrix formulation. This dynamic release mechanism maintains consistent plasma concentrations across different individuals by controlling the rate and extent of absorption, thereby improving pharmacokinetic reliability while preserving adequate drug availability
Solution Approach 2:
The patent changes the release kinetics parameter from immediate to controlled release through matrix formulation design. This parameter change in release profile reduces interindividual variability by providing a more predictable and sustained absorption pattern, improving treatment consistency while maintaining therapeutic drug levels
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ASDs provide stable nilotinib compositions with reduced food interactions, improved dissolution, and lower inter-subject variability, ensuring safe and effective drug delivery without regard to food consumption, while maintaining therapeutic efficacy at lower doses.
Implementation Method 1
an amorphous solid dispersion (ASD) comprising nilotinib and at least one polymeric stabilizing and matrix-forming component
Implementation Method 2
at least one polymeric stabilizing and matrix-forming component
Implementation Method 3
at least one solid organic acid in admixture with the ASD
Data Source
AI summary
Disclosed herein is a composition comprising: an amorphous solid dispersion (ASD) comprising nilotinib and at least one polymeric stabilizing and matrix-forming component; and at least one solid organic acid in admixture with the ASD, and uses thereof in the treatment of proliferative disorder.